ICU Medical, Inc. (ICUI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ICU Medical, Inc. (ICUI) Healthcare & Pipeline Overview

ICU Medical, Inc. is a global leader in infusion therapy and critical care solutions, providing a comprehensive range of medical devices and software. With a focus on patient safety and infection prevention, the company serves acute care hospitals, ambulatory clinics, and alternate site facilities worldwide, maintaining a strong presence in the medical instruments and supplies sector.

What Is the Investment Thesis for ICUI?

The company's consistent revenue generation from a diverse product portfolio and global customer base offers stability. Key value drivers include the increasing demand for infection control products in healthcare settings and the growing adoption of IV medication safety software. Growth catalysts include strategic acquisitions and partnerships, expansion into emerging markets, and continued innovation in infusion therapy technologies. However, investors should be aware of potential risks such as regulatory changes, competition from larger medical device companies, and fluctuations in healthcare spending. With a market capitalization of $3.93B and a P/E ratio of 131.05, ICU Medical's financial performance warrants close monitoring.

Based on FMP financials and quantitative analysis

ICUI Key Highlights

Market Cap of $3.93B reflects ICU Medical's established position in the medical device industry.

• P/E ratio of 131.05 indicates investor expectations for future earnings growth.
• Gross Margin of 36.4% demonstrates the company's ability to maintain profitability in a competitive market.
• The company's focus on needlefree technology and infection control aligns with current healthcare priorities.
• ICU Medical's global presence allows it to capitalize on growth opportunities in various international markets.

Who Are ICUI's Competitors?

ICUI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ICUI's Key Strengths?

Specialized expertise in infusion therapy and critical care

• Strong focus on patient safety and infection control
• Global presence and distribution network
• Comprehensive product portfolio

What Are ICUI's Weaknesses?

Relatively small market capitalization compared to larger competitors

• Reliance on a limited number of key products
• Exposure to regulatory changes and healthcare spending fluctuations
• Profit Margin of 2.1% is relatively low

What Could Drive ICUI Stock Higher?

Potential FDA approvals for new infusion therapy devices could expand the product portfolio.

• Increasing demand for infection control products due to heightened awareness of healthcare-associated infections.
• Expansion into emerging markets, particularly in Asia and Latin America, could drive revenue growth.
• Strategic partnerships with hospitals and healthcare systems to implement IV medication safety software.

What Are the Key Risks for ICUI?

Rich valuation — a P/E of 131.05 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $7.2M recently.
• Regulatory changes in the medical device industry could impact product approvals and market access.
• Competition from larger medical device companies with greater resources.
• Fluctuations in healthcare spending and reimbursement policies could affect demand for ICU Medical's products.
• Product liability claims related to the use of medical devices.
• Supply chain disruptions could impact manufacturing and distribution.

What Are the Growth Opportunities for ICUI?

• Expansion of IV Medication Safety Software: ICU Medical's MedNet platform offers a significant growth opportunity. As hospitals increasingly integrate electronic health records (EHRs) and seek to improve medication management, the demand for IV medication safety software is expected to rise. The global market for healthcare IT solutions is projected to reach $440 billion by 2027. By expanding the functionality of MedNet and integrating it with other hospital systems, ICU Medical can capture a larger share of this market.
• Strategic Acquisitions and Partnerships: ICU Medical can drive growth through strategic acquisitions and partnerships. By acquiring companies with complementary technologies or expanding into new geographic markets, ICU Medical can broaden its product portfolio and customer base. The company has a history of successful acquisitions, and further strategic deals could accelerate its growth trajectory. Identifying and integrating synergistic businesses will be critical for success.
• Penetration of Emerging Markets: Emerging markets offer significant growth opportunities for ICU Medical. As healthcare infrastructure improves in countries like China, India, and Brazil, the demand for advanced medical devices is expected to increase. By establishing a presence in these markets and tailoring its products to local needs, ICU Medical can tap into a new source of revenue growth. This expansion requires careful navigation of regulatory requirements and cultural differences.
• Innovation in Infusion Therapy Technologies: Continued innovation in infusion therapy technologies is essential for ICU Medical's long-term growth. By developing new and improved products that address unmet clinical needs, the company can maintain its competitive edge and capture market share. This includes developing smart infusion pumps with advanced features, as well as new needlefree connectors and closed system transfer devices. Investing in research and development is crucial for driving innovation.
• Focus on Infection Control: The increasing emphasis on infection control in healthcare settings presents a significant growth opportunity for ICU Medical. The company's needlefree connectors, disinfecting caps, and closed system transfer devices help to reduce the risk of healthcare-associated infections (HAIs). As hospitals face increasing pressure to reduce HAIs, the demand for these products is expected to rise. By promoting the benefits of its infection control products and expanding its sales efforts, ICU Medical can capitalize on this trend.

What Are ICUI's Competitive Advantages?

• Specialization in infusion therapy and critical care creates a focused expertise.
• Established relationships with hospitals and healthcare providers provide a strong distribution network.
• Proprietary technologies and patents protect its products from competition.
• Focus on patient safety and infection control enhances brand reputation.

What Does ICUI Do?

Founded in 1984 and headquartered in San Clemente, California, ICU Medical, Inc. has evolved into a prominent player in the medical device industry. The company develops, manufactures, and sells a wide array of medical devices and related products used in infusion therapy and critical care applications. Its product portfolio includes needlefree connectors marketed under brands like MicroClave and NanoClave, catheter patency devices, disinfecting caps such as SwabCap and SwabTip, and hemodialysis connectors like Tego. ICU Medical also offers closed system transfer devices under the ChemoClave and ChemoLock brands, as well as the Diana hazardous drug compounding system. In addition to these specialized devices, ICU Medical provides a range of IV therapy and diluents, including sodium chloride, dextrose, and balanced electrolyte solutions. Irrigation solutions, infusion pumps (Plum 360 and LifeCare PCA), and IV medication safety software (ICU Medical MedNet) are also integral to their offerings. The company's critical care products include hemodynamic monitoring systems, cardiac output monitoring catheters, blood pressure transducers, and closed blood sampling systems. ICU Medical serves a diverse customer base, including acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities such as outpatient clinics, home health care providers, and long-term care facilities. The company's global reach and comprehensive product line position it as a key supplier in the healthcare industry.

What Products and Services Does ICUI Offer?

• Develops and manufactures medical devices for infusion therapy.
• Offers critical care products for hemodynamic monitoring.
• Provides needlefree connectors to reduce infection risks.
• Sells IV therapy and diluent solutions.
• Offers infusion pumps and related software.
• Provides closed system transfer devices for hazardous drugs.
• Offers irrigation solutions for various medical procedures.

How Does ICUI Make Money?

• ICU Medical generates revenue through the sale of medical devices and related products.
• The company sells its products to hospitals, clinics, and other healthcare facilities.
• Recurring revenue is generated through the sale of disposable products, such as needlefree connectors and IV solutions.
• The company also generates revenue from service contracts and software licenses.

What Industry Does ICUI Operate In?

ICU Medical operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and stringent regulatory oversight. The global market for medical devices is projected to reach $600 billion by 2026, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. Key competitors include larger medical device companies with broader product portfolios. ICU Medical differentiates itself through its specialization in infusion therapy and critical care, as well as its focus on patient safety and infection prevention. The industry is also influenced by trends such as the increasing adoption of telehealth and remote patient monitoring, which may create new opportunities for ICU Medical's IV medication safety software.

Who Are ICUI's Key Customers?

• Acute care hospitals
• Wholesalers
• Ambulatory clinics
• Outpatient clinics
• Home healthcare providers
• Long-term care facilities

Over the past six months, ICU Medical, Inc. insiders filed 30 SEC Form 4 transactions — 20 sales and 10 purchases. On net that is roughly 35K shares disposed (about $7.2M), a signal worth weighing alongside the fundamentals.

ICU Medical, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 30.7% above estimates on average.

ICU Medical, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.36 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for ICU Medical, Inc. stands at 1.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.8%, showing how much profit it generates from its asset base. ICUI trades at a trailing price-to-earnings ratio of 131.05, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.43 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.7%, the inverse of the P/E and a quick read on earnings relative to price.

ICU Medical, Inc. (ICUI) Valuation Context

Valued at $3.93B, ICUI is classified as a mid-cap stock. Analyst price targets span from $163.00 to $200.00, with a consensus of $186.40. At the current price of $157.26, that implies approximately 19% upside potential. Relative to its peer group, ICUI's quantitative score of 64/100 is roughly in line with the peer average of 61/100.

ICUI Revenue & Earnings Trend

In Q2 FY2026, ICUI generated $551.7M in top-line revenue, marking a sequential increase of 4.0%. The company recorded net income of $19.1M, with diluted EPS of $0.76. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ICUI averaged $0.29 in diluted EPS.

Company Profile

ICU Medical, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in San Clemente, US. The company is led by CEO Vivek Jain. ICUI has traded publicly since 1992.

ICUI Financials

ICUI Latest News

ICUI Analyst Consensus

ICUI MoonshotScore

ICUI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources